ArticleJournal of nanobiotechnology2026
Application of an intercellular adhesion molecule-1-targeted nanoparticles loaded with irisin in postoperative neurocognitive disorder through metabolic axis activation and barrier restoration.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Postoperative neurocognitive disorder (PND) is a frequent complication in elderly surgical patients and is closely associated with blood-brain barrier (BBB) disruption and cerebral metabolic imbalance. The present study explores a metabolism-based therapeutic strategy using an Irisin nanoparticle delivery system to restore postoperative cerebral energy homeostasis, repair BBB integrity, and mitigate neuroinflammation and cognitive impairment. In a PND mouse model, an Intercellular adhesion molecule-1-targeted nanoparticle loaded with Irisin (ICAM-1-NP@Irisin) was evaluated. Targeted delivery enabled preferential accumulation of Irisin within postoperative inflammatory endothelium, resulting in enhanced tight junction protein expression, increased cerebral ATP levels, and improved cognitive performance. Mechanistic analyses demonstrated activation of the AMPK/PGC-1α/SIRT1/UCP2 metabolic axis, which promoted endothelial repair while suppressing glial activation and neuronal apoptosis. Integrated multi-omics profiling revealed expansion of reparative endothelial cell subpopulations, supporting a regulatory framework linking metabolism, barrier connectivity, and cognition. Collectively, these findings identify ICAM-1-NP@Irisin as a promising brain-protective strategy for PND that integrates metabolic modulation with precision nanodelivery, offering translational insights into postoperative brain dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.